Search hospitals > Oregon > Portland
Providence Cancer Center at Providence Portland Medical Center
Claim this profilePortland, Oregon 97213
Global Leader in Breast Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Lung Cancer
Conducts research for Solid Tumors
165 reported clinical trials
9 medical researchers
Summary
Providence Cancer Center at Providence Portland Medical Center is a medical facility located in Portland, Oregon. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Lung Cancer, Solid Tumors and other specialties. Providence Cancer Center at Providence Portland Medical Center is involved with conducting 165 clinical trials across 186 conditions. There are 9 research doctors associated with this hospital, such as Rachel Sanborn, MD, Matthew Taylor, MD, Brendan D. Curti, MD, and Rom S. Leidner, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
Rachel Sanborn, MDProvidence Portland Medical Center4 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Cancer
42 reported clinical trials
67 drugs studied
Matthew Taylor, MDProvidence Portland Medical Center3 years of reported clinical research
Studies Melanoma
Studies Squamous Cell Carcinoma
18 reported clinical trials
32 drugs studied
Brendan D. Curti, MDProvidence Portland Medical Center1 year of reported clinical research
Studies Melanoma
Studies Cancer
14 reported clinical trials
26 drugs studied
Rom S. Leidner, MDProvidence Cancer Institute Franz Clinic4 years of reported clinical research
Studies Squamous Cell Carcinoma
Studies Cancer
14 reported clinical trials
30 drugs studied
Clinical Trials running at Providence Cancer Center at Providence Portland Medical Center
Non-Small Cell Lung Cancer
Cancer
Solid Tumors
Squamous Cell Carcinoma
Tumors
Breast Cancer
Non-Hodgkin's Lymphoma
Colorectal Cancer
Melanoma
Renal Cell Carcinoma
FF-10832 + Pembrolizumab
for Cancer
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Recruiting3 awards Phase 2
BAY2927088
for Non-Small Cell Lung Cancer
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments: * BAY 2927088 twice every day as a tablet by mouth, or * Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment. During the study, the doctors and their study team will: * take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer * check the overall health of the participants by performing tests such as blood and urine tests, and checking * heart health using an electrocardiogram (ECG) * perform pregnancy tests for women * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Recruiting2 awards Phase 33 criteria
BA3071 + Nivolumab
for Cancer
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Recruiting2 awards Phase 1 & 27 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Providence Cancer Center at Providence Portland Medical Center?
Providence Cancer Center at Providence Portland Medical Center is a medical facility located in Portland, Oregon. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Lung Cancer, Solid Tumors and other specialties. Providence Cancer Center at Providence Portland Medical Center is involved with conducting 165 clinical trials across 186 conditions. There are 9 research doctors associated with this hospital, such as Rachel Sanborn, MD, Matthew Taylor, MD, Brendan D. Curti, MD, and Rom S. Leidner, MD.